Past, present and future drug treatment for rheumatoid arthritis and systemic lupus erythematosus

Immunology and Cell Biology

Volumn 81, Issue 5, 2003, Pages 350-353

  Mottram, Patricia L ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

Author keywords

Autoimmune disease; Rheumatoid arthritis; Systemic lupus erythematosus; Treatments

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; AURANOFIN; AUROTHIOMALATE; AZATHIOPRINE; CELECOXIB; CHLORAMBUCIL; CHLOROQUINE; CORTISONE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DEXAMETHASONE; DOXYCYCLINE; ETANERCEPT; HYDROCORTISONE; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ROFECOXIB; TACROLIMUS; THALIDOMIDE; UNINDEXED DRUG;

AUTOIMMUNITY; DRUG MECHANISM; GASTROINTESTINAL SYMPTOM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL RESEARCH; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMALARIALS; ARTHRITIS, RHEUMATOID; GLUCOCORTICOIDS; GOLD; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PLANT BARK; PLANT EXTRACTS; TUBERCULOSIS;

EID: 0141890067     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1711.2003.01184.x     Document Type: Review

References (26)

1. Arthritis Foundation. 2003; Available from URL: http:// www.arthritis.org
2. Vane JR, Botting RM. Mechanism of action of nonsteroidal antiinflammatory drugs. Am. J. Med. 1998; 104: 2S-8S; discussion 21S-2S.
3. Rodnan GP, Benedek TG. The early history of antirheumatic drugs. Arthritis Rheum. 1970; 13: 145-65.
4. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 1998; 38: 97-120.
5. Pap T, van der Laan WH, Aupperle KR et al. Modulation of fibroblast-mediated cartilage degradation by articular chondrocytes in rheumatoid arthritis. Arthritis Rheum. 2000; 43: 2531-6.
6. Fox RI, Kang HI. Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus 1993; 2: S9-S12.
7. Ruddy S, Harris E, Sledge B eds. Arthritis related to infection. In: Kelley's Textbook of Rheumatology, Vol. 2 6th edn. Philadelphia, USA: WB Saunders, 2001; 1469-539.
8. Svartz N. Salazopyrin, a new sulfanilamide preparation. Acta. Med. Scand. 1942; 110: 577-9.
9. O'Dell JR, Haire CE, Erikson N et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N. Engl. J. Med. 1996; 334: 1287-91.
10. O'Dell JR, Haire CE, Palmer W et al. Treatment of early rheumatoid arthritis with minocycline or placebo: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1997; 40: 842-8.
11. Reveille JD, Alarcon GS, Fowler SE et al. HLA-DRB1 genes and disease severity in rheumatoid arthritis. The MIRA Trial Group. Minocycline Rheumatoid Arthritis. Arthritis Rheum. 1996; 39: 1802-7.
12. Angulo JM, Sigal LH, Espinoza LR. Coexistent minocycline-induced systemic lupus erythematosus and autoimmune hepatitis. Semin. Arthritis Rheum. 1998; 28: 187-92.
13. Forestier J. Rheumatoid arthritis and its treatment by gold salts. J. Lab. Med. 1935; 20: 827-30.
14. Ward JR, Williams HJ, Egger MJ et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum. 1983; 26: 1303-15.
15. Stein M. Immunoregulatory drugs. In: Ruddy S, Harris E, Sledge E, (eds) Kelley's Textbook of Rheumatology, Vol. 1 6th edn, Philadelphia, USA: WB Saunders, 2001; 879-98.
16. O'Dell JR, Haire C, Erikson N et al. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J. Rheumatol. 1996; 44 (Suppl): 72-4.
17. Nakazawa F, Matsuno H, Yudoh K et al. Methotrexate inhibits rheumatoid synovitis by inducing apoptosis. J. Rheumatol. 2001; 28: 1800-8.
18. Barrera P, Boerbooms AM, Janssen EM et al. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum. 1993; 36: 1070-9.
19. Hench P. The reversibility of certain rheumatic and non-rheumatic conditions by the use of cortisone or of the pituitary adenocorticotropic hormone. Ann. Intern. Med. 1952; 39: 1818-27.
20. Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum. Dis. Clin. North Am. 1993; 19: 123-51.
21. Walker MG. Z391g is co-expressed with activated macrophage genes. Biochim. Biophys. Acta. 2002; 1574: 387-90.
22. Haraoui B, Strand V, Keystone E. Biologic agents in the treatment of rheumatoid arthritis. Curr. Pharm. Biotechnol. 2000; 1: 217-33.
23. Hogarth PM. Fc receptors are major mediators of antibody based inflammation in autoimmunity. Curr. Opin. Immunol. 2002; 14: 798-802.
24. Maxwell KF, Powell MS, Hulett MD et al. Crystal structure of the human leukocyte Fc receptor, Fc gammaRIIa. Nat. Struct. Biol. 1999; 6: 437-42.
25. Powell MS, Barton PA, Emmanouilidis D et al. Biochemical analysis and crystallisation of Fc gamma RIIa, the low affinity receptor for IgG. Immunol. Lett. 1999; 68: 17-23.
26. Pietersz GA, Powell M, Ramsland PA, Hogarth PM. Fc receptor structure and the design of anti-inflammatories. New therapeutics for autoimmune disease. Annu. Reports Med. Chem. 2002; 37: 217-24.